News & Media
Media
FEATURED
Learn more about our ACCUM technology
Making a Global Impact
News Releases
Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates
Montreal, QC, Canada, October 1st, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum®...
Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
Montreal, QC, Canada, September 29, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum®...
Defence Therapeutics Provides Updates on Sharing Agreement
Montreal, QC, Canada, September 28, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”) (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum®...
Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders
Montreal, QC, Canada, September 8, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum®...
Defence Therapeutics Provides Updates on Sharing Agreement
Montreal, QC, Canada, September 4, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to provide an update on its sharing...
Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs
Montreal, QC, Canada, August 31st, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum®...
Defence Therapeutics Strengthens Radiopharmaceutical Leadership With Appointment Of Dr. Ryan Simms As Chief Operating Officer And Head Of Radiopharmaceutical Programs
Montreal, QC, Canada, August 17, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum®...
Defence Therapeutics Appoints Dr. Amie Phinney As President And Chief Executive Officer
Montreal, QC, Canada, August 4, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum®...
Defence Therapeutics Opens New Office In Hamilton To Expand Its Accum Radiopharmaceutical Platform
Montreal, QC, Canada, July 8, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology,...
Defence Therapeutics To Participate In Bio International Convention 2026 Next Week For Strategic Partnership Discussions
Montreal, QC, Canada, June 17th, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce its participation in the BIO...
Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver To Its Board Of Directors
Montreal, QC, Canada, June 3rd, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John...
Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert To Its Board Of Directors
Montreal, QC, Canada, June 1st, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John...